Stifel analyst Paul Matteis reiterated a Buy rating on BioMarin Pharmaceutical Inc. (NASDAQ: BMRN), following CHMP approval recommendation for the ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE